Novo Nordisk and AWS bring agentic AI into drug discovery

Novo Nordisk is expanding its use of AWS artificial intelligence tools across drug discovery, including AI agents for target identification, therapy design, and research workflows.

Under the agreement announced recently, AWS will become Novo Nordisk’s preferred cloud provider and strategic AI partner. The companies have also created a co-innovation hub at Novo Nordisk’s existing London facility, where AWS engineers and Novo Nordisk scientists will work directly with the pharmaceutical company’s data and research insights.

The London hub will bring Novo Nordisk R&D staff together with AWS engineers, AI specialists, applied scientists, and professional services teams. AWS said the arrangement is intended to reduce handoffs between computational analysis and laboratory research as potential drug candidates move through early development.

Thilde Hummel Bøgebjerg, executive vice president of Enterprise IT & Quality at Novo Nordisk, said the partnership combines AI technology with the company’s scientific expertise.

“AI has the potential to transform how we discover, develop and deliver medicines, but r...